Precigen Posts First-Ever Profit on $53.1M PAPZIMEOS Revenue, Sees Cash Flow Break-Even by Year-End
PGEN has more than doubled off its 52-week low of $1.7.
Summary
Precigen achieved its first profitable quarter with $20.1 million in net income on $53.1 million PAPZIMEOS revenue, guiding to cash flow break-even by year-end 2026.
Updates
· SEC 10-Q — The 10-Q reports total revenues of $54.98 million for Q2 2026, including $53.26 million product revenue and $1.72 million service revenue, with net income of $20.07 million.
Key Events · Earnings and Guidance · PGEN
-
First Profitable Quarter
Net income reached $20.1 million, or $0.05 per diluted share, a sharp turnaround from the $26.6 million net loss in Q2 2025.
-
PAPZIMEOS Revenue Surge
Broad US adoption and over 500 patient hub enrollments propelled PAPZIMEOS net revenue to $53.1 million, more than double the Q1 2026 figure.
-
Cash Flow Break-Even Guidance
With $38.7 million in cash on hand and growing PAPZIMEOS revenue, management expects to fund operations through cash flow break-even by the end of 2026.
-
FDA Market Exclusivity
The FDA granted PAPZIMEOS seven-year market exclusivity, offering long-term protection against prospective competition.
Analysis · PGEN · Life Sciences
A landmark quarter for Precigen: Q2 2026 delivered the company's first profit, with net income reaching $20.1 million as PAPZIMEOS sales surged to $53.1 million—more than double the prior quarter. This performance shifts the narrative from a pre-revenue biotech to a self-sustaining commercial enterprise. Bolstered by $38.7 million in cash and investments, management now expects to reach cash flow break-even by the end of 2026, removing near-term survival risk. Seven-year FDA market exclusivity and accelerating commercial adoption further cement the transformation, a shift the market has already rewarded with the stock trading near its 52-week high.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PGEN was trading at $7.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $1.70 to $6.80. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.